Loading...
•
Nov 30, 2024
Neogen Q2 2025 Earnings Report
Neogen's second quarter reflected steady progress with improvement across the business, core revenue growth accelerating in both segments, sequential margin expansion, and significantly better free cash flow.
Key Takeaways
Neogen Corporation announced preliminary results for Q2 2025, with revenue of $231.3 million. The company reported a net loss of $456.3 million due to a non-cash goodwill impairment, but adjusted net income was $24.4 million, or $0.11 per diluted share. The company is updating its full-year outlook.
Revenue reached $231.3 million, a 0.7% increase compared to the previous year.
Net loss was $456.3 million, or $(2.10) per diluted share, due to a non-cash goodwill impairment charge.
Adjusted Net Income was $24.4 million, or $0.11 per diluted share.
Adjusted EBITDA was $51.4 million.
Revenue by Segment
Forward Guidance
The company is updating its full-year outlook. Revenue is now expected to be in the range of $905 million to $925 million. Adjusted EBITDA is now expected to be in the range of $205 million to $215 million.
Challenges Ahead
- Strengthening of the U.S. dollar.
- A delay in the ramp-up of sample collection production.
- The voluntary attrition of genomics revenue related to restructuring activities.
- Lower revenue.
- Higher shipping and distribution costs.
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...